<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>BELEODAQ (belinostat) for injection - for Healthcare Professionals (HCPs)</title>
    <meta name="description" content="In the next round against relapsed or refractory PTCL, fight on with BELEODAQ. It is an HDAC inhibitor available for relapsed/refractory PTCL.">
    <!-- Favicon -->
    <link rel="icon" href="https://beleodaq.com/hcp/wp-content/uploads/2019/05/cropped-favicon-Beleodaq-32x32.png" sizes="32x32">
    <!-- Google fonts -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@300;400;600;700;800&family=Raleway:wght@700&display=swap" rel="stylesheet">
    <!-- CSS Reset -->
    <link rel="stylesheet" href="css/reset.css">
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/safety.css">
</head>
<body>
    <!-- Header -->
    <header class="header">
        <!-- Indications and Usage -->
        <div class="indications">
            <h5 class="indications__title">Indications and Usage</h5>
            <p class="indications__body copyright">BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon veriﬁcation and description of clinical beneﬁt in the conﬁrmatory trial.</p>
        </div>
        <!-- Navigation -->
        <nav class="nav">
            <!-- Logo -->
            <a class="nav__logo" href="index.html">
                <img src="https://beleodaq.com/hcp/wp-content/uploads/2019/04/logonew.png" alt="BELEODAQ® (belinostat) for injection: For injection in the treatment of relapsed or refractory PTCL">
            </a>
            <!-- Header Buttons -->
            <div class="nav__buttons">
                <!-- Site Buttons (redirecting to other parts of site) -->
                <ul class="site-buttons">
                    <li>
                        <a class="site-buttons__button p" href="#">
                            Important Safety Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button p"
                        href="#">
                           Prescribing Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button button--orange p" href="#">
                           Patient Site
                        </a>
                    </li>
                </ul>
                <!-- Nav Links and Dropdown Menus -->
                <ul class="navlinks">
                    <li>
                        <a class="navlinks__link p" href="ptcl.html">PTCL <br>Overview</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">About <br>Beleodaq</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">BELIEF <br>Trial</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="efficacy.html"><br>Efficacy</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Study design
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Baseline Characteristics
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Response Rate
                                </a>
                             </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Duration of Response
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li class="active">
                        <a class="navlinks__link--active p" href="safety.html">Safety & Tolerability</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Adverse Reactions
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Tolerability
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Dosing & Administration</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dosing Schedule
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dose Modifications
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Access & Resources</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    STAR
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Resources
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Contact <br>Us</a>
                    </li>
                </ul>
            </div>
        </nav>
    </header>
    <!-- Main -->
    <main>
        <h2 class="primary">Duration of Exposure and Incidence of Adverse Events (AEs)</h2>
       
        <h3 class="secondary-variant">AEs occurring in ≥10% of patients (N = 129) with R/R PTCL (NCI-CTCAE grades 1 to 4)<sup>1</sup></h3>

        <div class="patient-aes">
            <img src="assets/svg/safety-chart.svg" alt="AEs occurring in ≥10% of patients (N = 129) with R/R PTCL (NCI-CTCAE grades 1 to 4)">
            <ul>
                <li>
                    <h4 class="light">Most patients (113 of 129) remained on the target dose (1000 mg/m2)<sup>1,2</sup>
                    <ul>
                        <li>Dosage adjustments due to AEs occurred in 16 of 129 patient treated with BELEODAQ</li>
                    </ul>
                    </h4>
                </li>
                <li>
                    <h4 class="light">The relative dose intensity (doses administered vs planned) was 98%<sup>2</sup></h4>
                </li>
                <li>
                    <h4 class="light">Treatment duration ranged from 1 to 33 cycles (median, 2 cycles)<sup>1,2</sup></h4>
                </li>
                <li>
                    <h4 class="light">Twenty-five patients (19.4%) discontinued treatment with BELEODAQ due to AEs<sup>1</sup>
                        <ul>
                            <li>The AEs reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure</li>
                        </ul>
                    </h4>
                </li>
                <li>
                    <h4 class="light">Treatment-emergent AEs (TEAEs) occurred in 97% of patients and were generally mild to moderate in severity<sup>2</sup>
                    <ul>
                        <li>The most common AEs were nausea, fatigue, pyrexia, anemia, and vomiting</li>
                    </ul></h4>
                </li>
                <li>
                    <h4 class="light">Grade 3/4 AEs occurring in ≥5% of patients (N = 129) were anemia (11%), thrombocytopenia (7%), dyspnea (6%), and fatigue (5%)<sup>1</sup></h4>
                </li>
                <li>
                    <h4 class="light">47% (n = 61) experienced serious AEs (SAEs)<sup>1,2</sup>
                    <ul>
                        <li>
                            No clinically meaningful difference in SAEs was observed in patients based on age (&lt;65 years vs &lt;65 years or &lt;75 years vs ≥75 years)
                        </li>
                    </ul></h4>
                </li>
            </ul>
        </div>

        <p class="light">NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events. 
            Note: AEs are listed by order of incidence in the all-grades category first, then in the grades 3 to 4 category; measured by NCI-CTCAE version 3.0.
        </p>

        <h3 class="secondary-variant">Duration of response (DoR) was calculated using 2 methods<sup>1,2</sup></h3>
        <ul>
            <li>
                <h4 class="light">
                Calculations for both methods began when a patient first met response criteria (CR or PR)
                </h4>
            </li>
        </ul>
        <h4>DoR as determined by SAP criteria was used by the FDA to evaluate durability and is included in the required labeling
        </h4>
        <div class="sap-criteria">
            <div class="sap-data">
                <span class="jumbo">8.4</span>
                <span>months<sup>2</sup></span>
                <p>(n = 31/95% CI, 4.5-29.4)</p>
            </div>
            <div class="sap-text">
                <h3>SAP criteria</h3>
                <h4>DoR measured from the first date of response to PD or death</h4>
                <h4>DoR definition of SAP differs from the more commonly used IWG definition</h4>
            </div>
        </div>
        <h4>DoR as determined by IWG criteria is a post-hoc analysis and is not included in the prescribing information</h4>
        <ul>
            <li>
                <h4 class="light">
                IWG criteria: DoR measured from the first date of response to subsequent date that relapse or progression was documented with patients who died censored at their last tumor assessment
            </h4></li>
            <li class="sup"><h4 class="light">13.6 months<sup>1</sup> (n = 31/95% CI, 4.5-29.4)
            </h4></li>
        </ul>
        <div class="cr2">
            <h3 class="secondary-variant">
                Responses were observed in patients who achieved a CR2
            </h3>
            <div class="cr2__data">
                <div class="data__left">
                    <span class="jumbo">DoR >29</span>
                    <span>months<sup>1</sup></span>
                </div>
                <div class="data__right">
                    <h4>For those who achieved a CR (n = 13),</h4>
                    <h4>median DoR was not only reached but exceeded<sup>1</sup></h4>
                </div>
            </div>
        </div>
        <h4 class="light"><span class="semibold">BELEODAQ<sup>®</sup> (belinostat) is included in the NCCN<sup>®</sup> Guidelines</span> as a Category 2A preferred second-line and subsequent therapy for <span class="semibold">PTCL-NOS; AITL; EATL; MEITL; nodal PTCL, TFH;</span> and <span class="semibold">FTCL</span>, <u>regardless of intention to proceed to transplant</u><sup>3</sup>
        </h4>
        <ul>
            <li><h4 class="light">
                <span class="primary semibold">7.5%</span> of patients proceeded to HSCT after treatment with BELEODAQ2
            </h4></li>
        </ul>
        <p class="light">1. O’Connor O, et al. J Clin Oncol. 2015;33:2492-2499. 2. BELEODAQ® [Prescribing Information]. Acrotech Biopharma, LLC; January 2020. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for T-Cell Lymphomas V.1.2021. ©2021 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed February 25, 2021. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.
        </p>
        <div class="button-group">
            <a href="efficacy.html" class="button secondary">&larr; Previous</a>
            <a href="#" class="button">Safety & Tolerability&rarr;</a>
        </div>
    </main>
    <!-- ISI -->
    <footer>
        <section class="isi">
            <div>
                <h5 class="isi__header">Select Important Safety Information</h5>
                <p class="isi__body copyright"><span class="isi__body--bold ">Warnings and Precautions</span>
                    BELEODAQ can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary.</p>
            </div>
            <a class="isi__button p" href="#">
                See More <span>&uarr;</span>
            </a>
        </section>
    </footer>
    <!-- Vanilla JS -->
    <script src="js/app.js"></script>
</body>
</html>